SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 214 filers reported holding SAGE THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,601 | -56.2% | 175 | 0.0% | 0.00% | – |
| Q2 2023 | $8,228 | +12.1% | 175 | 0.0% | 0.00% | – |
| Q1 2023 | $7,343 | +104800.0% | 175 | -5.4% | 0.00% | – |
| Q4 2022 | $7 | -99.9% | 185 | 0.0% | 0.00% | – |
| Q3 2022 | $7,000 | +40.0% | 185 | +5.7% | 0.00% | – |
| Q2 2022 | $5,000 | -16.7% | 175 | -9.8% | 0.00% | – |
| Q1 2022 | $6,000 | -14.3% | 194 | +10.9% | 0.00% | – |
| Q4 2021 | $7,000 | 0.0% | 175 | 0.0% | 0.00% | – |
| Q3 2021 | $7,000 | -30.0% | 175 | 0.0% | 0.00% | – |
| Q2 2021 | $10,000 | -23.1% | 175 | 0.0% | 0.00% | – |
| Q1 2021 | $13,000 | -13.3% | 175 | 0.0% | 0.00% | – |
| Q4 2020 | $15,000 | +36.4% | 175 | 0.0% | 0.00% | – |
| Q3 2020 | $11,000 | +57.1% | 175 | 0.0% | 0.00% | – |
| Q2 2020 | $7,000 | +40.0% | 175 | 0.0% | 0.00% | – |
| Q1 2020 | $5,000 | -66.7% | 175 | -14.6% | 0.00% | -100.0% |
| Q4 2019 | $15,000 | – | 205 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Casdin Capital, LLC | 312,000 | $29,886,000 | 5.11% |
| DAFNA Capital Management LLC | 104,306 | $9,991,000 | 4.97% |
| Palo Alto Investors LP | 850,977 | $81,515,000 | 4.34% |
| BB BIOTECH AG | 1,375,229 | $131,733,000 | 4.22% |
| Eventide Asset Management | 936,000 | $89,659,000 | 3.97% |
| TRV GP II, LLC | 37,362 | $3,579,000 | 3.56% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 146,179 | $14,002,000 | 2.11% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 111,908 | $10,720,000 | 2.06% |
| OAK RIDGE INVESTMENTS LLC | 231,483 | $22,174,000 | 1.60% |
| Rhenman & Partners Asset Management AB | 137,339 | $13,156,000 | 1.50% |